Ftse Mib
34.171,69
0,03%
DAX
19.909,14
-0,25%
S&P 500
5.934,81
-0,60%
NASDAQ
19.586,56
-0,69%
Bitcoin
94.559,36
1,12%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Emergent Biosolutions Inc (EBS) Emergent Biosolutions Inc (EBS) Notizie

Emergent Biosolutions Inc

EBS
9,355
1,09 (13,12%)
Ultimo aggiornamento: 19:08:06
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/12/202423:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202414:00GLOBEEmergent BioSolutions Receives $50 Million Contract Option..
10/12/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
04/12/202422:45EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/12/202422:36EDGAR2Form S-1/A - General form for registration of securities..
21/11/202422:02EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/11/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:16EDGAR2Form 144 - Report of proposed sale of securities
12/11/202422:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/11/202422:06EDGAR2Form S-1 - General form for registration of securities under..
12/11/202416:34EDGAR2Form 144 - Report of proposed sale of securities
06/11/202422:49GLOBEEmergent BioSolutions Supports New Clinical Trial Evaluating..
06/11/202422:12EDGAR2Form 8-K - Current report
06/11/202422:05GLOBEEmergent BioSolutions Reports Third Quarter 2024 Financial..
04/11/202413:30GLOBEEmergent BioSolutions Appoints Dr. Simon Lowry as Chief..
23/10/202413:30GLOBEEmergent BioSolutions to Release Third Quarter 2024..
08/10/202423:32GLOBEEmergent BioSolutions Demonstrates Commitment to Increasing..
04/10/202413:29EDGAR2Form 8-K - Current report
02/10/202414:11EDGAR2Form 8-K - Current report
02/10/202413:30GLOBEEmergent BioSolutions Announces Closing of $100 Million..
26/9/202414:05GLOBEEmergent BioSolutions Announces the Execution of Contract..
25/9/202413:07GLOBEEmergent BioSolutions Confirms Approximately $400 million in..
17/9/202422:12EDGAR2Form 8-K - Current report
13/9/202412:45GLOBEEmergent BioSolutions Announces Agreement to Settle..
12/9/202414:30GLOBEEmergent BioSolutions Awarded Research and Development..
03/9/202413:47EDGAR2Form 8-K - Current report
03/9/202413:08GLOBEEmergent BioSolutions Successfully Refinances Debt & Further..
30/8/202414:16GLOBEEmergent BioSolutions Expands Ready to Rescue Initiative to..
30/8/202400:53GLOBEEmergent BioSolutions’ ACAM2000®, (Smallpox and Mpox..
20/8/202422:20EDGAR2Form 8-K - Current report
20/8/202417:30GLOBEEmergent BioSolutions Finalizes Sale of Baltimore-Camden..
19/8/202423:10GLOBEEmergent BioSolutions Responds to Mpox Public Health..
06/8/202423:01GLOBEEmergent BioSolutions Reports Second Quarter 2024 Financial..
06/8/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/8/202422:21EDGAR2Form 8-K - Current report
06/8/202414:00GLOBEEmergent BioSolutions Expands NARCAN® Nasal Spray..
31/7/202414:56EDGAR2Form 8-K - Current report
31/7/202414:53GLOBEEmergent BioSolutions Completes Sale of RSDL® (Reactive Skin..
30/7/202422:30EDGAR2Form 8-K - Current report
24/7/202413:30GLOBEEmergent BioSolutions Launches Opioid Emergency Preparedness..
23/7/202414:27GLOBEEmergent BioSolutions to Release Second Quarter 2024..
22/7/202414:00GLOBEEmergent BioSolutions Announces Shelf-Life Extension for..
12/7/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/7/202413:30GLOBEEmergent BioSolutions Continues to Drive Improved Financial..
08/7/202422:57EDGAR2Form 8-K - Current report
Apertura: 8,28 Min: 8,26 Max: 9,3847
Chiusura: 8,27

La tua Cronologia

NYSE
EBS
Emergent Biosolutions
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network